Montag & Caldwell LLC Upped Holding in Edwards Lifesciences Corp (EW) by $5.13 Million

June 24, 2018 - By Peter Erickson

Edwards Lifesciences Corporation (NYSE:EW) Logo

Montag & Caldwell Llc increased its stake in Edwards Lifesciences Corp (EW) by 4.11% based on its latest 2018Q1 regulatory filing with the SEC. Montag & Caldwell Llc bought 36,873 shares as the company’s stock declined 0.56% with the market. The institutional investor held 934,768 shares of the industrial specialties company at the end of 2018Q1, valued at $130.42 million, up from 897,895 at the end of the previous reported quarter. Montag & Caldwell Llc who had been investing in Edwards Lifesciences Corp for a number of months, seems to be bullish on the $32.22 billion market cap company. The stock increased 0.45% or $0.69 during the last trading session, reaching $152.87. About 1.11M shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 19.08% since June 24, 2017 and is uptrending. It has outperformed by 6.51% the S&P500.

Montag & Caldwell Llc, which manages about $14.22 billion and $2.75 billion US Long portfolio, decreased its stake in Schwab Charles (NYSE:SCHW) by 511,839 shares to 1.52 million shares, valued at $79.60 million in 2018Q1, according to the filing. It also reduced its holding in Fleetcor Technologies Inc (NYSE:FLT) by 45,187 shares in the quarter, leaving it with 378,442 shares, and cut its stake in Microsoft Corp (NASDAQ:MSFT).

More news for Edwards Lifesciences Corporation (NYSE:EW) were recently published by:, which released: “Midday Stock Roundup” on June 13, 2018.‘s article titled: “Don’t Let Go Of Hasbro – Cramer’s Lightning Round (6/5/18)” and published on June 06, 2018 is yet another important article.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

Among 16 analysts covering Edwards Lifesciences Corp (NYSE:EW), 13 have Buy rating, 0 Sell and 3 Hold. Therefore 81% are positive. Edwards Lifesciences Corp has $18000 highest and $135.0 lowest target. $153.92’s average target is 0.69% above currents $152.87 stock price. Edwards Lifesciences Corp had 23 analyst reports since January 2, 2018 according to SRatingsIntel. Jefferies maintained Edwards Lifesciences Corporation (NYSE:EW) on Thursday, February 1 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $174.0 target in Thursday, March 22 report. The stock has “Overweight” rating by Barclays Capital on Friday, February 2. The rating was downgraded by JP Morgan to “Neutral” on Tuesday, January 2. On Thursday, February 15 the stock rating was maintained by Canaccord Genuity with “Buy”. SunTrust maintained the stock with “Buy” rating in Tuesday, April 10 report. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Friday, February 2 by Guggenheim. On Wednesday, April 25 the stock rating was downgraded by Northland Capital to “Hold”. BMO Capital Markets maintained Edwards Lifesciences Corporation (NYSE:EW) on Wednesday, January 17 with “Buy” rating. JMP Securities maintained it with “Market Outperform” rating and $140 target in Friday, February 2 report.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: